Navigation Links
Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology

THE WOODLANDS, Texas, Aug. 10, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.  The issue also included an expert editorial discussing the study, its implications and the potential utility of this mechanism of action in gastrointestinal disease.

Results of the Phase 2 study showed that the tryptophan hydroxylase inhibitor, LX1031, was well tolerated and provided clinical benefit to patients with non-constipating IBS, showing improvements in a global assessment of adequate relief from IBS pain and discomfort and in stool consistency.  Notably, symptom relief correlated with reduced levels of 5-HIAA, a biomarker of serotonin production.

Lexicon recently completed a Phase 1 study of LX1033, a follow-on compound that is significantly more potent than LX1031.  In the study, LX1033 produced reductions in the 5-HIAA biomarker in healthy volunteers comparable to those seen with LX1031, but with lower and less frequent dosing.  Lexicon intends to advance LX1033 into a Phase 2 clinical trial as its lead drug candidate in IBS.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031 and LX1033, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX1031 and LX1033. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
2. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
3. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
4. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
5. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
6. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
7. Lexicon to Provide First Quarter 2011 Financial Results
8. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
9. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
11. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
Post Your Comments:
(Date:10/13/2015)... 2015 Health Gorilla ( ) today announced ... – a secure platform for clinical data and communications poised ... and manage healthcare in the US. The launch follows the ... combined total of $4.4M raised to date, with Data ... Ventures , Harris Barton , Orfin Ventures ...
(Date:10/13/2015)... , October 13, 2015 --> ... ,What can be expected from the Asthma and COPD Therapies ... rates? Visiongain ,s brand new report shows you potential ... ,  ,Our 309-page report provides 260 tables, charts, and graphs. ... future market prospects. Our new study lets you assess forecasted ...
(Date:10/13/2015)... SPRINGS, N.C. , Oct. 13, 2015  Yesterday ... NVS Influenza Vaccines Holly Springs manufacturing site located in ... Since 2014, the facility has produced Flucelvax ® ... has the potential for faster start-up and is not ... 2015 CSL Limited acquired the influenza vaccines business of ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... "My friend's ... his fists into his infected cheeks," said an inventor from Platteville, Colo. "I came ... skin problems." , He developed the UNTOUCHABLE to prevent a child from rubbing or ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... of anesthesia and pain management services, today announced its partnership with WPC ... integrates data from disparate systems and organizes the data into an aggregated data ...
(Date:10/13/2015)... ... ... According to an article published October 5th by the American ... weight with a bariatric procedure are much less likely to develop endometrial cancer, which ... from 40 to 50 percent of all endometrial cancer cases are caused by obesity, ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG ... Summit, GPUG Summit and NAVUG Summit are independent user conferences designed and led ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... provider of IBM software products, introduced a new company, RightSensorâ„¢ LLC, an Internet ... data communications capability. RightSensorâ„¢ provides a fully-managed approach for customers requiring sensor ...
Breaking Medicine News(10 mins):